Evidence map›Paper›PMID 41385070›Full record

ArticleIndian journal of pediatrics2026

Pattern and Persistence of Islet Autoantibodies and their Immunogenetic Association among Type 1 Diabetes Patients from North India.

Shreya Sharma, Alpesh Goyal, Uma Kanga, Neeraj Kumar, Dona Maria Philips, Pradeep A Praveen, Ravinder Goswami, Nikhil Tandon

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shreya SharmaDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Alpesh GoyalDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Uma KangaDepartment of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India.
Neeraj KumarIndian Council of Medical Research (ICMR)-National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India.
Dona Maria PhilipsDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Pradeep A PraveenDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Ravinder GoswamiDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Nikhil TandonDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India. nikhil_tandon@hotmail.com.ORCID 0000-0003-4604-1986

Funding

Endocrine Society of India Endocrine Society of IndiaIndian Council of Medical Research Indian Council of Medical Research
6 · The paper itself

Abstract

objectivesTo determine the prevalence and persistence of islet autoantibodies and explore their HLA associations among patients with type 1 diabetes (T1DM).

methodsIslet autoantibodies (GAD-65A, IA-2A, and ZnT8A) and fasting C-peptide (FCP) levels were assessed at baseline (prevalence) and 2-5 y, 5-10 y, and > 10 y from the baseline (persistence). HLA associations were evaluated for individual islet autoantibodies and their persistence.

resultsThe authors evaluated 366 participants with a median diabetes duration of 6 y at baseline. The overall positivity for any of the three autoantibodies was 67.5%, which increased to 76% in a subset of patients (n = 125) with diabetes duration ≤ 2 y. In the persistence analysis, positivity for IA-2A and ZnT8A declined earlier compared to GAD-65A (median survival times of 11, 12, and 31 y). The median survival time for FCP (time to undetectable levels) was 5 y, with significantly shorter survival in individuals with younger (< 10 y) age at diagnosis and in the autoantibody-positive group. The HLA-DRB1*03 allele was significantly associated with the GAD-65A, and the HLA-DRB1*04 allele with the ZnT8A. There was no association of HLA-DRB1 status with islet autoantibody persistence.

conclusionsNearly two in every three patients evaluated at a median disease duration of 6 y tested positive for one or more islet autoantibodies. GAD-65A was more prevalent and relatively stable over time, serving as a robust diagnostic marker for T1DM. A more rapid decline in beta cell reserve was noted in individuals with younger age at diagnosis and islet autoantibody positivity.

Indexed as

AutoantibodiesDiabetes Mellitus, Type 1Islets of LangerhansAdolescentChildChild, PreschoolC-PeptideFemaleGlutamate DecarboxylaseHLA-DRB1 ChainsHumansIndiaMaleZinc Transporter 8AutoantibodiesC-PeptideGlutamate DecarboxylaseHLA-DRB1 ChainsSLC30A8 protein, humanZinc Transporter 8C-peptideGAD-65HLAIslet autoantibodyPersistenceType 1 diabetes

Identifiers

PMID41385070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.